文章核心观点 - 约翰逊 & 约翰逊(JNJ)股价在最新交易中下跌1.24%,低于标普500指数1.19%的涨幅[1] - 过去一个月,该公司股价下跌0.62%,低于医疗行业3.54%和标普500指数3.35%的涨幅[2] - 分析师预计该公司将在2024年7月17日公布的季度财报中,每股收益为2.73美元,同比下降2.5%;营收为223.7亿美元,同比下降12.38%[3] - 全年来看,分析师预计该公司每股收益为10.64美元,同比增长7.26%;营收为882.8亿美元,同比下降5.1%[4] 根据相关目录分别进行总结 公司表现 - 约翰逊 & 约翰逊股价在最新交易中下跌1.24%,低于大盘涨幅[1] - 过去一个月,该公司股价下跌0.62%,低于医疗行业和大盘的涨幅[2] - 分析师预计该公司将在2024年7月公布的季度财报中,每股收益和营收均同比下降[3] - 全年来看,该公司每股收益预计增长7.26%,营收预计下降5.1%[4] 行业表现 - 医疗行业过去一个月涨幅为3.54%,高于该公司股价下跌0.62%[2] - 大盘标普500指数过去一个月涨幅为3.35%,高于该公司股价下跌0.62%[2] - 该公司所属的大型制药行业目前在所有行业中排名靠后,位于底部41%[10][11]

文章核心观点 - 强生公司(JNJ)已向美国食品药品监督管理局(FDA)提交了一项补充新药申请(sNDA),寻求扩大其HIV-1疗法Prezcobix在较小儿童中的使用[1][2][3] - Prezcobix是一种两药固定剂量组合片剂,用于治疗HIV-1感染的治疗未经治疗和治疗经验的成人和青少年患者,体重至少40公斤[2] - 强生公司还与吉利德科学公司(GILD)合作开发了一种新的组合片剂,含有针对较小儿童的重量调整的达芦那韦剂量(达芦那韦675毫克/可伯西斯特150毫克)[4] - 除了Prezista和Prezcobix/Rezolsta,强生公司还销售一种达芦那韦为基础的每日单片剂(STR)疗法Symtuza[5] - 除了强生公司和吉利德科学公司,GSK公司(GSK)通过其HIV子公司ViiV Healthcare也是HIV市场的另一个主要参与者,主要销售多药物和双药物疗法[6] 行业概况 - 强生公司的股价今年迄今下跌5.7%,而行业整体上涨17.3%[2] - GSK公司的HIV销售额在2023年以固定汇率计算增长13%,预计2024年将以高个位数到低双位数的幅度增长[6] - 生物通公司(BVS)是医疗保健行业中的一只排名靠前的股票,目前拥有Zacks第1级(强烈买入)评级[8][9] - 生物通公司在过去60天内,2024年的每股收益预测从16美分上升至27美分,2025年的每股收益预测也从40美分上升至43美分,今年迄今其股价上涨27.1%[8][9] - 生物通公司在过去4个季度中有3个季度的收益超出预期,平均收益惊喜率为151.67%[10]

Johnson & Johnson (JNJ) announced positive topline results from the pivotal late-stage MDD3001 study, which evaluated its investigational oral drug seltorexant in patients with major depressive disorder (MDD) with insomnia symptoms.The MDD3001 study evaluated the drug as an adjunctive treatment to baseline antidepressants in adult and elderly patients who did not benefit from antidepressants alone. The study met all its primary and secondary endpoints.Treatment with seltorexant achieved statistically signif ...

NEW YORK, May 29, 2024 /PRNewswire/ -- Sarepta Therapeutics Inc. (NASD: SRPT) will replace Shockwave Medical Inc. (NASD: SWAV) in the S&P MidCap 400 effective prior to the opening of trading on Monday, June 3. S&P 500 constituent Johnson & Johnson (NYSE: JNJ) is acquiring Shockwave Medical in a deal expected to be completed soon pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       ...

Johnson & Johnson (NYSE:JNJ) Bernstein's 40th Annual Strategic Decisions Conference Call May 29, 2024 1:30 PM ET Company Participants Joaquin Duato - Chairman and Chief Executive Officer Conference Call Participants Lee Hambright - Bernstein Lee Hambright Okay. Thanks, everybody. Welcome back from lunch. I'm Lee Hambright, US MedTech Analyst at Bernstein. And we are thrilled to host Johnson & Johnson's Chairman and CEO, Joaquin Duato. Thank you so much for being here. Joaquin Duato Thank you. Lee Hambright ...

Johnson & Johnson (JNJ) announced a definitive agreement with Swiss biotech Numab Therapeutics to acquire global rights to NM26, a phase II-ready bispecific antibody for atopic dermatitis (“AD”). To execute the deal, Numab Therapeutics will spin off its wholly-owned subsidiary called Yellow Jersey Therapeutics, which holds NM26 rights, to its shareholders. J&J will acquire Yellow Jersey Therapeutics from Numab’s shareholders for a purchase price of $1.25 billion in cash.AD is a common inflammatory disease c ...

J&J will gain full rights to develop, manufacture and commercialize NM26 globally for the treatment of atopic dermatitis and follow-on indications Under the agreement terms, J&J will pay $1.25 billion to acquire Yellow Jersey Therapeutics, which holds NM26 rights NM26 is a Phase 2-ready bi-specific antibody from Numab's pipeline of candidates, discovered and engineered using its proprietary MATCH™ technology platform HORGEN, Switzerland, May 28, 2024 (GLOBE NEWSWIRE) -- Numab Therapeutics AG (Numab), a clin ...

文章核心观点 - 公司最近一个交易日的股价下跌1.82%,低于标普500指数0.7%的涨幅[1] - 公司过去一个月的股价上涨1.96%,低于医疗行业3.27%和标普500指数4.03%的涨幅[2] - 公司即将发布的财报预计每股收益将下降2.5%,收入将下降12.38%[3] - 全年来看,公司每股收益和收入分别预计增长7.26%和下降5.1%[4] - 分析师对公司的预测有所下调,这反映了短期业务趋势的变化[5][6] - 公司目前的市盈率略高于行业平均水平,PEG比率也高于行业平均[8][9] - 公司所属的大型制药行业目前在所有行业中排名靠后[10][11]

In today’s uncertain market, securing investment returns is essential to protect your wealth from future downturns. Three businesses stand out as islands of stability amid geopolitical unrest and economic uncertainty. These massive companies in the industry provide defensive equities that are attractive buys for investors looking to strengthen their holdings. The first one shows substantial expansion in margins and profit growth. As a fundamental requirement, its diverse range of medical equipment and medic ...

NEW YORK — A group of cancer victims sued Johnson & Johnson JNJ.N on Wednesday, accusing the healthcare company of committing fraud through repeated and continued efforts to use a shell company’s bankruptcy to resolve tens of thousands of lawsuits alleging its talc products contained asbestos and caused cancer.Five plaintiffs who seek to represent over 50,000 people who have sued J&J over its talc products filed the proposed class action in New Jersey federal court. 3 J&J has said that its baby powder an ...